Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes

Kirsty J. McLean, Ker R. Marshall, Alison Richmond, Iain S. Hunter, Kay Fowler, Tobias Kieser, Sudagar S. Gurcha, Gurdal S. Besra, Andrew W. Munro

    Research output: Contribution to journalArticlepeer-review

    Abstract

    The genome sequence of Mycobacterium tuberculosis has revealed the presence of 20 different cytochrome P450 mono-oxygenases (P450s) within this organism, and subsequent genome sequences of other mycobacteria and of Streptomyces coelicolor have indicated that these actinomycetes also have large complements of P450s, pointing to important physiological roles for these enzymes. The actinomycete P450s include homologues of 140α-sterol demethylases, the targets for the azole class of drugs in yeast and fungi. Previously, this type of P450 was considered to be absent from bacteria. When present at low concentrations in growth medium, azole antifungal drugs were shown to be potent inhibitors of the growth of Mycobacterium smegmatis and of Streptomyces strains, indicating that one or more of the P450s in these bacteria were viable drug targets. The drugs econazole and clotrimazole were most effective against M. smegmatis (MIC values of
    Original languageEnglish
    Pages (from-to)2937-2949
    Number of pages12
    JournalMicrobiology
    Volume148
    Issue number10
    Publication statusPublished - Oct 2002

    Keywords

    • Azole drugs
    • CYP121
    • P450 inhibitors
    • Tuberculosis

    Fingerprint

    Dive into the research topics of 'Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes'. Together they form a unique fingerprint.

    Cite this